Triple-negative breast cancer (TNBC) is a subtype of breast cancer that does not have three commonly targeted characteristics: estrogen receptors (ER), progesterone receptors (PR), and excess HER2 protein. Because hormone therapies and many HER2-targeted treatments do not work against TNBC, treatment often relies on chemotherapy, immunotherapy, surgery, radiation, and other approaches selected according to the stage and characteristics of the cancer. Anyone who notices a persistent breast lump, nipple change, unusual discharge, skin dimpling, or another unexplained breast change should seek medical evaluation.
Breast cancer cells can be tested for receptors and proteins that influence how the cancer grows and which treatments may work.
Triple-negative breast cancer tests negative for:
TNBC accounts for a smaller proportion of breast cancers than hormone receptor-positive disease. It can occur at any age but is more frequently diagnosed in younger women compared with some other breast cancer subtypes.
Symptoms of TNBC are generally similar to those of other breast cancers.
Possible signs include:
Early breast cancer may cause no symptoms, which is one reason appropriate screening is important.
A breast lump or other breast change does not automatically indicate cancer, but persistent or unexplained changes should be medically evaluated.
Diagnosis commonly involves breast imaging followed by a biopsy.
Testing may include:
The pathology report helps determine whether the tumor meets the criteria for triple-negative breast cancer.
Once TNBC is confirmed, doctors determine the stage.
Staging considers:
Stages range from stage 0 to stage IV, with stage IV indicating metastatic disease.
Staging is important because treatment for early-stage TNBC can differ significantly from treatment for metastatic TNBC.
Treatment is individualized according to stage, tumor characteristics, overall health, genetic findings, and previous therapy.
Chemotherapy remains an important treatment for many people with TNBC.
It may be administered before surgery, known as neoadjuvant therapy, to shrink the tumor and treat microscopic cancer cells throughout the body.
Chemotherapy may also be used after surgery to reduce the risk of recurrence.
Immunotherapy has become an important treatment for certain patients with TNBC.
Immune checkpoint inhibitors can help the immune system recognize and attack cancer cells. Pembrolizumab is used in specific treatment settings for certain early-stage and advanced TNBC cases.
Whether immunotherapy is appropriate depends on the cancer stage and other clinical factors.
Surgery may involve removing the tumor through breast-conserving surgery or removing the breast through mastectomy.
Lymph nodes may also be evaluated to determine whether cancer has spread beyond the breast.
The choice of surgery depends on tumor size, location, breast characteristics, patient preferences, and other factors.
Radiation therapy uses high-energy radiation to destroy remaining cancer cells in a specific area.
It is frequently used after breast-conserving surgery and may also be recommended after mastectomy in selected patients.
Although TNBC lacks ER, PR, and HER2 targets, some tumors contain other molecular features that can be targeted.
For example, certain patients with inherited BRCA1 or BRCA2 mutations may be candidates for PARP inhibitor therapy.
Other targeted treatments may be considered for advanced disease based on specific tumor characteristics.
When TNBC spreads to distant organs, it is called metastatic or stage IV breast cancer.
Common sites of spread can include:
Treatment for metastatic TNBC generally focuses on controlling the cancer, reducing symptoms, maintaining quality of life, and extending survival.
Treatment can include chemotherapy, immunotherapy, targeted medicines, antibody-drug conjugates, radiation, or combinations of these approaches.
Genetic testing can be particularly relevant for people diagnosed with TNBC.
Inherited changes in genes such as BRCA1 and BRCA2 can increase breast and ovarian cancer risk and may influence treatment decisions.
Genetic information can also have implications for close biological relatives, making genetic counseling useful in appropriate situations.
TNBC has historically been associated with a higher risk of recurrence than some hormone receptor-positive breast cancers, particularly during the first several years after diagnosis.
However, prognosis varies substantially.
Important factors include:
A strong response to treatment given before surgery can be an encouraging sign in early-stage TNBC.
Regular follow-up is important after treatment.
Medical care may include:
The follow-up schedule depends on the stage and treatment history.
Triple-negative breast cancer is a distinct breast cancer subtype defined by the absence of estrogen receptors, progesterone receptors, and excess HER2 protein. These characteristics mean that conventional hormone therapies and HER2-directed treatments are generally not effective against TNBC, making accurate pathology testing especially important.
Treatment has changed significantly in recent years. Chemotherapy remains a central treatment, while immunotherapy, targeted medicines, antibody-drug conjugates, surgery, and radiation therapy have expanded the approaches available for selected patients. For early-stage disease, treatment may begin with chemotherapy and immunotherapy before surgery, followed by additional treatment depending on the response and pathology findings.
For advanced or metastatic TNBC, treatment is selected according to factors such as previous therapy, tumor biomarkers, genetic mutations, overall health, and the organs affected. Molecular testing can identify characteristics that may make certain targeted or immune-based treatments appropriate.
Genetic testing is also important for many people with TNBC because inherited changes such as BRCA1 or BRCA2 mutations can influence cancer risk, treatment decisions, and family counseling.
Although TNBC can behave more aggressively than some other breast cancer subtypes, individual outcomes vary considerably. Earlier-stage disease, effective treatment response, and advances in modern therapies can all influence prognosis. Continued research into tumor biology, immunotherapy, targeted treatments, and new drug combinations is creating additional possibilities for people with TNBC.